Patents by Inventor Angelo Corti

Angelo Corti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NGR CONJUGATES AND USES THEREOF
    Publication number: 20230181719
    Abstract: The present invention relates to a conjugate comprising a first peptide of sequence CNGRCG (SEQ ID NO: 1) linked to the N-terminus of a protein and a compound X linked to the N-terminus of said peptide and to related medical uses.
    Type: Application
    Filed: March 19, 2021
    Publication date: June 15, 2023
    Applicant: OSPEDALE SAN RAFFAELE S.R.L.
    Inventors: Flavio CURNIS, Angelo CORTI, Andrès J. M. FERRERI
  • CHROMOGRANIN A-DERIVED PEPTIDES AND USES THEREOF
    Publication number: 20220402980
    Abstract: The present invention refers to chromogranin A-derived peptides that are potent dual ligands for integrins ?v?6 and av?8, their therapeutic and diagnostic uses and relative compositions.
    Type: Application
    Filed: November 16, 2020
    Publication date: December 22, 2022
    Applicant: OSPEDALE SAN RAFFAELE S.R.L.
    Inventors: Flavio CURNIS, Angelo CORTI, Giovanna MUSCO, Michela GHITTI, Francesca NARDELLI, Alessandro GORI
  • COMBINED TREATMENT OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Publication number: 20220008513
    Abstract: The present invention refers to the combination of an R-CHOP therapy with an administration of NGR-hTNF or an analog thereof for the treatment of primary central nervous system lymphoma, preferably relapsed/refractory primary central nervous system lymphoma.
    Type: Application
    Filed: December 2, 2019
    Publication date: January 13, 2022
    Applicant: FONDAZIONE CENTRO SAN RAFFAELE
    Inventors: Angelo CORTI, Andrés José Maria FERRERI
  • Immunoconjugates for the treatment of tumours
    Patent number: 9782496
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: October 10, 2017
    Assignee: MolMed SpA
    Inventors: Angelo Corti, Flavio Curnis
  • Peptides for inhibiting tumor growth
    Patent number: 9561289
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclized by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 7, 2017
    Assignee: OSPEDALE SAN RAFFAELE SRL
    Inventors: Angelo Corti, Flavio Curnis
  • Immunoconjugates for the Treatment of Tumours
    Publication number: 20160074537
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Application
    Filed: July 29, 2015
    Publication date: March 17, 2016
    Inventors: Angelo Corti, Flavio Curnis
  • Immunoconjugates for the treatment of tumours
    Patent number: 9119886
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: September 1, 2015
    Assignee: MolMed SpA
    Inventors: Angelo Corti, Flavio Curnis
  • PEPTIDES
    Publication number: 20150045302
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Angelo Corti, Flavio Curnis
  • PEPTIDES COMPRISING AN ISODGR MOTIF
    Publication number: 20110076234
    Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
    Type: Application
    Filed: July 14, 2010
    Publication date: March 31, 2011
    Inventors: ANGELO CORTI, FLAVIO CURNIS
  • Immunoconjugates for the Treatment of Tumours
    Publication number: 20100310506
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Application
    Filed: April 30, 2010
    Publication date: December 9, 2010
    Applicant: MolMed Spa
    Inventors: Angelo Corti, Flavio Curnis
  • Peptides comprising an isoDGR motif
    Patent number: 7795386
    Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: September 14, 2010
    Assignees: Molmed SpA, Fondazione Centro San Raffaele del Monte Tabor
    Inventors: Angelo Corti, Flavio Curnis
  • MODIFIED CYTOKINES FOR USE IN CANCER THERAPY
    Publication number: 20100196458
    Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
    Type: Application
    Filed: October 27, 2009
    Publication date: August 5, 2010
    Inventor: Angelo CORTI
  • Modified cytokines for use in cancer therapy
    Patent number: 7622556
    Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: November 24, 2009
    Assignee: Fondazione Centro San Raffaele Del Monte Tabor
    Inventor: Angelo Corti
  • Modified cytokines for use in cancer therapy
    Patent number: 7622105
    Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
    Type: Grant
    Filed: January 25, 2006
    Date of Patent: November 24, 2009
    Assignee: Fondazione Centro San Raffaele Del Monte Tabor
    Inventor: Angelo Corti
  • Tumor-targeted drug delivery systems and uses thereof
    Publication number: 20090092663
    Abstract: The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems.
    Type: Application
    Filed: August 29, 2008
    Publication date: April 9, 2009
    Applicants: G. Gaslini Children's Hospital, Fondazione Centro San Raffaele Del Monte Tabor, The Governors of the University of Alberta
    Inventors: Mirco Ponzoni, Angelo Corti, Theresa M. Allen
  • Conjugation Product
    Publication number: 20090068106
    Abstract: A peptide which selectively inhibits ?v?3 integrin which comprises the deamidation product of a peptide comprising the NGR motif.
    Type: Application
    Filed: December 21, 2005
    Publication date: March 12, 2009
    Inventors: Angelo Corti, Flavio Curnis
  • Tumor-targeted drug delivery systems and uses thereof
    Patent number: 7479483
    Abstract: The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: January 20, 2009
    Assignees: G. Gaslini Children's Hospital, Fondazione Centro San Raffaele del Monte, University of Alberta
    Inventors: Mirco Ponzoni, Angelo Corti, Theresa M. Allen
  • Modified cytokines for use in cancer therapy
    Patent number: 7476721
    Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
    Type: Grant
    Filed: June 27, 2005
    Date of Patent: January 13, 2009
    Assignee: Fondazione Centro San Raffaele Del Monte Tabor
    Inventor: Angelo Corti
  • Modified cytokines for use in cancer therapy
    Patent number: 7309694
    Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: December 18, 2007
    Assignee: Fondazione Centro San Raffaele Del Monte Tabor
    Inventor: Angelo Corti
  • Modified cytokines for use in cancer therapy
    Publication number: 20070041939
    Abstract: Cytokine derivatives capable of homing the tumoral vessels and the antigen presenting cells and the use thereof as antitumoral agents.
    Type: Application
    Filed: October 25, 2006
    Publication date: February 22, 2007
    Inventor: Angelo Corti